Literature DB >> 23812487

ACOG Committee Opinion No. 566: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination.

.   

Abstract

In the face of dramatic and persistent increases in pertussis disease in the United States, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its guidelines for the use of the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) for pregnant women. The new guidance was issued based on an imperative to minimize the significant burden of pertussis disease in vulnerable newborns, the reassuring safety data on the use of Tdap in adults, and the evolving immunogenicity data that demonstrate considerable waning of immunity after immunization. The revised Advisory Committee on Immunization Practices guidelines recommend that health care personnel administer a dose of Tdap during each pregnancy, irrespective of the patient's prior history of receiving Tdap. To maximize the maternal antibody response and passive antibody transfer and levels in the newborn, optimal timing for Tdap administration is between 27 weeks and 36 weeks of gestation, although Tdap may be given at any time during pregnancy. However, there may be compelling reasons to vaccinate earlier in pregnancy. There is no evidence of adverse fetal effects from vaccinating pregnant women with an inactivated virus or bacterial vaccines or toxoids, and a growing body of robust data demonstrates safety of such use. For women who previously have not received Tdap, if Tdap was not administered during pregnancy it should be administered immediately postpartum to the mother in order to reduce the risk of transmission to the newborn. Additionally, other family members and planned direct caregivers also should receive Tdap as previously recommended (sustained efforts at cocooning). Given the rapid evolution of data surrounding this topic, immunization guidelines are likely to change over time and the American College of Obstetricians and Gynecologists will continue to issue updates accordingly.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812487     DOI: 10.1097/01.AOG.0000431054.33593.e3

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  23 in total

1.  Clinician perspectives on strategies to improve patient maternal immunization acceptability in obstetrics and gynecology practice settings.

Authors:  Paula M Frew; Laura A Randall; Fauzia Malik; Rupali J Limaye; Andrew Wilson; Sean T O'Leary; Daniel Salmon; Meghan Donnelly; Kevin Ault; Matthew Z Dudley; Vincent L Fenimore; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2018-02-15       Impact factor: 3.452

2.  Perinatal management of fetal supraventricular tachycardia complicated by maternal pertussis.

Authors:  Stephanie Dejong; Bahram Salmanian; Alireza A Shamshirsaz; Rodrigo Ruano
Journal:  BMJ Case Rep       Date:  2015-07-07

3.  Rubella Surveillance and Diagnostic Testing among a Low-Prevalence Population, New York City, 2012-2013.

Authors:  Beth M Isaac; Jane R Zucker; Francesca R Giancotti; Emily Abernathy; Joseph Icenogle; Jennifer L Rakeman; Jennifer B Rosen
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

Review 4.  Maternal immunization. Clinical experiences, challenges, and opportunities in vaccine acceptance.

Authors:  Michelle H Moniz; Richard H Beigi
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

5.  Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.

Authors:  Flor M Munoz; Leonard E Weisman; Jennifer S Read; George Siberry; Karen Kotloff; Jennifer Friedman; Rosemary D Higgins; Heather Hill; Harry Seifert; Mirjana Nesin
Journal:  Clin Infect Dis       Date:  2014-12-15       Impact factor: 9.079

6.  Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.

Authors:  Raïssa Nadège Caboré; Kirsten Maertens; Alexandre Dobly; Elke Leuridan; Pierre Van Damme; Kris Huygen
Journal:  Virulence       Date:  2017-02-22       Impact factor: 5.882

Review 7.  Bordetella pertussis pathogenesis: current and future challenges.

Authors:  Jeffrey A Melvin; Erich V Scheller; Jeff F Miller; Peggy A Cotter
Journal:  Nat Rev Microbiol       Date:  2014-03-10       Impact factor: 60.633

8.  Message framing strategies to increase influenza immunization uptake among pregnant African American women.

Authors:  Heather A Marsh; Fauzia Malik; Eve Shapiro; Saad B Omer; Paula M Frew
Journal:  Matern Child Health J       Date:  2014-09

9.  Tdap vaccine attitudes and utilization among pregnant women from a high-risk population.

Authors:  Amanda F Dempsey; Sarah E Brewer; Carter Sevick; Jennifer Pyrzanowski; Sara Mazzoni; Sean T O'Leary
Journal:  Hum Vaccin Immunother       Date:  2015-10-02       Impact factor: 3.452

10.  Low Uptake of Human Papillomavirus Vaccine Among Postpartum Women, 2006-2012.

Authors:  Kimberly A Kilfoyle; Lisa Rahangdale; Stacie B Dusetzina
Journal:  J Womens Health (Larchmt)       Date:  2016-07-22       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.